KRAS and non-small cell lung carcinoma: A previous study on non-small-cell lung cancer with KRAS mutations reported that induction of DNA damage and apoptosis by WEE1 inhibitors occurs only in the presence of p53 mutations because the PI3K–AKT pathway is inhibited by WEE1 inhibitors only in the presence of p53 mutations [33].